These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 21047194)

  • 1. Effectiveness of buprenorphine maintenance treatment as compared to a syringe exchange program among buprenorphine misusing opioid-dependent patients.
    Aalto M; Visapää JP; Halme JT; Fabritius C; Salaspuro M
    Nord J Psychiatry; 2011 Sep; 65(4):238-43. PubMed ID: 21047194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Illicit buprenorphine use, interest in and access to buprenorphine treatment among syringe exchange participants.
    Fox AD; Chamberlain A; Sohler NL; Frost T; Cunningham CO
    J Subst Abuse Treat; 2015 Jan; 48(1):112-6. PubMed ID: 25205666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discontinuation of buprenorphine maintenance therapy: perspectives and outcomes.
    Bentzley BS; Barth KS; Back SE; Book SW
    J Subst Abuse Treat; 2015 May; 52():48-57. PubMed ID: 25601365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medication-assisted treatment with buprenorphine: assessing the evidence.
    Thomas CP; Fullerton CA; Kim M; Montejano L; Lyman DR; Dougherty RH; Daniels AS; Ghose SS; Delphin-Rittmon ME
    Psychiatr Serv; 2014 Feb; 65(2):158-70. PubMed ID: 24247147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Six-Year Outcome of Opioid Maintenance Treatment in Heroin-Dependent Patients: Results from a Naturalistic Study in a Nationally Representative Sample.
    Soyka M; Strehle J; Rehm J; Bühringer G; Wittchen HU
    Eur Addict Res; 2017; 23(2):97-105. PubMed ID: 28376505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Harm Reduction Agencies as a Potential Site for Buprenorphine Treatment.
    Fox AD; Chamberlain A; Frost T; Cunningham CO
    Subst Abus; 2015; 36(2):155-60. PubMed ID: 25837290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Buprenorphine maintenance treatment retention improves nationally recommended preventive primary care screenings when integrated into urban federally qualified health centers.
    Haddad MS; Zelenev A; Altice FL
    J Urban Health; 2015 Feb; 92(1):193-213. PubMed ID: 25550126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder.
    Fox AD; Maradiaga J; Weiss L; Sanchez J; Starrels JL; Cunningham CO
    Addict Sci Clin Pract; 2015 Jan; 10(1):2. PubMed ID: 25592182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Two-year follow-up of an opioid-user cohort treated with high-dose buprenorphine (Subutex)].
    Fhima A; Henrion R; Lowenstein W; Charpak Y
    Ann Med Interne (Paris); 2001 Apr; 152 Suppl 3():IS26-36. PubMed ID: 11435992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Malmö Treatment Referral and Intervention Study (MATRIS)—effective referral from syringe exchange to treatment for heroin dependence: a pilot randomized controlled trial.
    Bråbäck M; Nilsson S; Isendahl P; Troberg K; Brådvik L; Håkansson A
    Addiction; 2016 May; 111(5):866-73. PubMed ID: 26613636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrating Buprenorphine Into an Opioid Treatment Program: Tailoring Care for Patients With Opioid Use Disorders.
    Polydorou S; Ross S; Coleman P; Duncan L; Roxas N; Thomas A; Mendoza S; Hansen H
    Psychiatr Serv; 2017 Mar; 68(3):295-298. PubMed ID: 27745534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Awareness of, experience with, and attitudes toward buprenorphine among opioid users visiting a New York City syringe exchange program.
    Shah PA; Sohler NL; López C; Fox AD; Cunningham CO
    J Opioid Manag; 2013; 9(6):407-13. PubMed ID: 24481929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome evaluation of the opioid agonist maintenance treatment in Iran.
    Esmaeili HR; Ziaddinni H; Nikravesh MR; Baneshi MR; Nakhaee N
    Drug Alcohol Rev; 2014 Mar; 33(2):186-93. PubMed ID: 24428135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Buprenorphine Treatment and 12-step Meeting Attendance: Conflicts, Compatibilities, and Patient Outcomes.
    Monico LB; Gryczynski J; Mitchell SG; Schwartz RP; O'Grady KE; Jaffe JH
    J Subst Abuse Treat; 2015 Oct; 57():89-95. PubMed ID: 25986647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 'Too little dose - too early discontinuation?'-Effect of buprenorphine dose on short term treatment adherence in opioid dependence.
    Muruganandam P; Shukla L; Sharma P; Kandasamy A; Chand P; Murthy P
    Asian J Psychiatr; 2019 Aug; 44():58-60. PubMed ID: 31325758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of early childhood trauma on retention and phase advancement in an outpatient buprenorphine treatment program.
    Kumar N; Stowe ZN; Han X; Mancino MJ
    Am J Addict; 2016 Oct; 25(7):542-8. PubMed ID: 27629823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine--programme description and policy implications.
    Bruce RD; Dvoryak S; Sylla L; Altice FL
    Int J Drug Policy; 2007 Aug; 18(4):326-8. PubMed ID: 17689382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of buprenorphine maintenance treatment in a French cohort of HIV-infected injecting drug users.
    Carrieri MP; Rey D; Loundou A; Lepeu G; Sobel A; Obadia Y;
    Drug Alcohol Depend; 2003 Oct; 72(1):13-21. PubMed ID: 14563539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Description and outcomes of a buprenorphine maintenance treatment program integrated within Prevention Point Philadelphia, an urban syringe exchange program.
    Bachhuber MA; Thompson C; Prybylowski A; Benitez J; Mazzella S; Barclay D
    Subst Abus; 2018; 39(2):167-172. PubMed ID: 29474119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous misuse of buprenorphine: characteristics and extent among patients undergoing drug maintenance therapy.
    Moratti E; Kashanpour H; Lombardelli T; Maisto M
    Clin Drug Investig; 2010; 30 Suppl 1():3-11. PubMed ID: 20450240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.